Stephen Bruce, MD
Family Medicine · Ogden, UTNPI 1841269321
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Amarin Pharma, Inc. at 25.4% of the total. Reporting peaked in 2021 at $1,367 and has fallen 98.5% since, to $20 in 2025.
Across 187 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$738
- AbbVie$483
- Astellas Pharma US Inc$164
- Lilly USA, LLC$156
- AstraZeneca$156
- GSK$142
- plus $1K from 24 others
Across 25 payments — averaging $27,514 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$470K
- Diasorin Molecular LLC$167K
- Sanofi Pasteur Inc.$51K
What the payments were for
- Food & beverage$2,79896%
- Education$1064%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 49 | $738 |
| AbbVie(2 entities) | 29 | $483 |
| Astellas Pharma US Inc | 5 | $164 |
| Lilly USA, LLC | 12 | $156 |
| AstraZeneca | 12 | $156 |
| GSK | 10 | $142 |
| Amgen | 6 | $106 |
| Biohaven Pharmaceuticals, Inc. | 5 | $94 |
| Sanofi-aventis U.S. LLC | 6 | $91 |
| E.r. Squibb & Sons, L.L.C. | 6 | $85 |
| Dynavax Technologies Corporation | 4 | $71 |
| Boehringer Ingelheim | 4 | $64 |
| Pfizer | 4 | $59 |
| Genentech USA, Inc. | 4 | $58 |
| Axsome Therapeutics, Inc. | 1 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $49 |
| Johnson & Johnson | 3 | $46 |
| Jazz Pharmaceuticals Inc. | 3 | $43 |
| Eisai Inc. | 3 | $35 |
| Qiagen, LLC | 2 | $28 |
| Novartis | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Novo Nordisk | 2 | $25 |
| Merck | 2 | $23 |
| Si-bone, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Biogen | 1 | $15 |
| Medtronic | 1 | $12 |
| Antares Pharma, Inc. | 1 | $12 |
| Assertio Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$125
How this compares
$2,904 in reported general payments places this provider in the 75th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $53,401 |
| MyrbetriqMirabegron | 53 | $26,416 |
| FarxigaDapagliflozin Propanediol | 27 | $17,497 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $11,344 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $11,024 |
| JardianceEmpagliflozin | 15 | $8,852 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,385 |
| Gabapentin | 146 | $4,449 |
| Duloxetine Hcl | 113 | $3,891 |
| Atorvastatin Calcium | 196 | $3,609 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 58 | $2,806 |
| Pantoprazole Sodium | 114 | $2,791 |
| Bupropion XlBupropion Hcl | 71 | $2,575 |
| Quetiapine Fumarate | 116 | $2,444 |
| Tamsulosin Hcl | 73 | $2,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59 | $53,40191 claims |
| Astellas Pharma US IncMyrbetriq | $164 | $26,41653 claims |
| AstraZenecaFarxiga | $156 | $17,49727 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $91 | $11,34413 claims |
| Boehringer IngelheimJardiance | $64 | $8,85215 claims |
| GSKTrelegy Ellipta | $142 | $8,38512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 928 family medicine providers in Utah.
Other family medicine in Ogden
- Brett BlaserOgden$12K
- Nathan PhelpsOgden$11K
- James BledsoeOgden$9K
- Michael WoolmanOgden$8K
- Charles RichardsonOgden$8K
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Scott EricksonBountiful$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.